Hisense announced that it recently received a "Notice of Approval for Drug Clinical Trial" from the National Medical Products Administration (NMPA). The company's independently developed oral, potent, and highly selective drug, HSK47388 tablets, is intended for the treatment of autoimmune diseases. Preclinical study results showed that HSK47388 exhibited significant efficacy in a rat enteritis model, along with good tolerability and a wide safety window. This application marks another new clinical trial application for HSK47388 tablets in the field of autoimmune diseases, potentially providing a new treatment option for patients with autoimmune diseases.